Search Results

By Caroline Helwick  / Wednesday, August 21, 2013 1:02 PM

Best of ASCO 2013: VeriStrat Assay May Help Select NSCLC Patients for Second-Line Therapy

VeriStrat, a serum-based protein assay, can help select which patients with non–small cell lung cancer (NSCLC) who are not known to have epidermal growth factor receptor (EGFR) mutations might benefit from an EGFR-targeted agent, according to a study described at the 2013 Best of ASCO Los...